vutiglabridin (HSG4112) / Glaceum - LARVOL DELTA

A multicenter, double-blind, randomized, placebo-controlled, phase 2a clinical trial of Vutiglabridin in Early-Stage Parkinson’s Disease (MDS Congress 2026) - No abstract available

Clinical • Late-breaking abstract • P2a data • CNS Disorders • Movement Disorders • Parkinson's Disease

Effect of glabridin on ion transport across primary human bronchial epithelial cells (NACFC 2026) - "Our results provide the first demonstration that glabridin can potentiate K+ secretion in human airway. As modulation of K+ channels has been proposed as a therapeutic approach in airway disease, our work sheds light on a potential mechanism of action for glabridin. In addition, these data provide the first evidence that glabridin and its synthetic derivative vutiglabridin act on the ubiquitously-expressed BKCa channel – a fact that may explain the diverse action of glabridin."

Asthma • Immunology • Infectious Disease • Respiratory Diseases

Effect of Glabridin on Ion Transport Across Primary Human Bronchial Epithelial Cells. (PubMed, Am J Physiol Cell Physiol) - "In contrast, the glabridin derivative, vutiglabridin failed to stimulate K+ secretion and inhibited the glabridin-dependent K+ secretory current...In summary, we show that glabridin both stimulates BKCa-dependent K+ secretion and inhibits cAMP-mediated Cl⁻ secretion across HBEs. These findings support a role for BKCa in the therapeutic effects of glabridin in airway."

Journal • Asthma • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • KCNN4

Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight. (PubMed, Int J Obes (Lond)) - "These findings demonstrate that Vutiglabridin can normalize body composition in combination with multiple GLP-1 RAs, highlighting its potential as a novel therapeutic option for obesity treatment."

Journal • Genetic Disorders • Obesity

A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients (clinicaltrials.gov) - P2 | N=99 | Completed | Sponsor: Glaceum | Recruiting ➔ Completed | Trial completion date: Jun 2026 ➔ Jan 2026

Trial completion • Trial completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

Mitochondria-Targeted Therapy for AMD: Strategy of Senolytic and Systemic Redox Restoration (ARVO 2026) - "Conclusions Mitochondria-targeted senolysis (Mito-K2) and mitochondrial redox restoration (Vutiglabridin) independently ameliorate RPE senescence and mitochondrial dysfunction in AMD models. Combining these complementary mitochondrial strategies may provide promising therapeutic potential for AMD."

Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • HIF1A • KDR

PHASE 2A TRIAL OF VUTIGLABRIDIN IN EARLY PARKINSON'S DISEASE: TARGETING AUTOPHAGY VIA PON2 ACTIVATION (ADPD 2026) - P2 | "This trial aims to validate the therapeutic efficacy of Vutiglabridin in early-stage PD by translating robust preclinical findings into clinical outcomes."

P2a data • CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease

Targeting PON2 with Vutiglabridin Restores Mitochondrial Integrity and Attenuates Oxidative Stress-Induced Senescence. (PubMed, Antioxidants (Basel)) - "The present study demonstrates that vutiglabridin alleviates oxidative stress-induced cellular senescence by preserving mitochondrial integrity and redox balance via a PON2-dependent mechanism. This study lends further support to the investigation of the PON2 pathway as a therapeutic target in age-related cellular dysfunction."

Journal • Metabolic Disorders • CDKN1A

Vutiglabridin ameliorates obesity by directly reducing fat mass through AMPK/lipophagy activation in adipocytes. (PubMed, Biomed Pharmacother) - "Multi-omics analyses, including proteomic and transcriptomic profiling of epididymal WAT in DIO-mice, further confirmed this mechanism. Collectively, these findings demonstrate that VUTI represents a promising therapeutic strategy for obesity by inducing fat-selective reduction via AMPK-mediated lipophagy."

Journal • Genetic Disorders • Obesity • AMPK

Neurotherapeutic effects of Vutiglabridin as a Paraoxonase-2 modulator in preclinical models of Parkinson's disease. (PubMed, Mol Neurodegener) - "These findings indicate that Vutiglabridin may serve as a promising therapeutic approach for reducing reactive oxygen species (ROS) levels by modulating PON2 activity in Parkinson's diseases."

Journal • Preclinical • CNS Disorders • Inflammation • Metabolic Disorders • Movement Disorders • Parkinson's Disease

Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects. (PubMed, Br J Clin Pharmacol) - "Vutiglabridin presented higher peak plasma concentrations but lower systemic exposure in obese subjects than in healthy females. Additionally, a modest downward trend in body weight was observed in obese subjects relative to healthy female subjects. These findings support further long-term phase II clinical trials."

Clinical • Journal • PK/PD data • Genetic Disorders • Inflammation • Obesity

A Study to Assess the Efficacy and Safety of Vutiglabridin in Knee Osteoarthritis Patients (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Glaceum | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Osteoarthritis • Pain • Rheumatology

Enhancing Mitochondrial Function to Mitigate RPE Senescence (ARVO 2025) - "Its effects relied on a protective protein, PON2. Vutiglabridin shows promise as a potential AMD therapy targeting RPE aging."

Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • CDKN2A

Targeting Paraoxonase-2: A potential strategy to mitigate cigarette smoke-induced RPE mitochondrial dysfunction and retinal degeneration. (ARVO 2025) - "PON2 silencing and pharmacological upregulation using either vutiglabridin (VG) or HM-10/10 were utilized in mechanistic studies...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Age-related Macular Degeneration • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders

A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Glaceum | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease

A Study to Assess the Efficacy and Safety of Vutiglabridin in Knee Osteoarthritis Patients (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Glaceum

New P2 trial • Immunology • Osteoarthritis • Pain • Rheumatology

Paraoxonase-2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitis. (PubMed, Br J Pharmacol) - "Our data demonstrated that VUTI is a promising therapeutic for NASH. Targeting PON2 may be important for improving liver function in various immune-metabolic diseases including NASH."

Journal • Fibrosis • Genetic Disorders • Hepatology • Immunology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients (clinicaltrials.gov) - P2 | N=90 | Not yet recruiting | Sponsor: Glaceum

New P2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Glaceum | Recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Study to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients (clinicaltrials.gov) - P2 | N=81 | Completed | Sponsor: Glaceum | Active, not recruiting ➔ Completed | Phase classification: P2a ➔ P2 | Trial completion date: Dec 2022 ➔ Apr 2023

Phase classification • Trial completion • Trial completion date • Genetic Disorders • Obesity

Effects of meal type on the bioavailability of vutiglabridin, a novel anti-obesity agent, in healthy subjects. (PubMed, Clin Transl Sci) - "The study drug was well-tolerated after administration in both the fed and fasted states. Food ingestion substantially increased the extent of oral vutiglabridin absorption in healthy subjects, and this enhancement increased with the fat content of the meal."

Journal • Genetic Disorders • Obesity

Vutiglabridin Alleviates Cellular Senescence with Metabolic Regulation and Circadian Clock in Human Dermal Fibroblasts. (PubMed, Antioxidants (Basel)) - "Our results demonstrate the significant senescence-alleviating effects of vutiglabridin, specifically with the restoration of cellular circadian rhythmicity and metabolic regulation. These data support the potential development of vutiglabridin against aging-associated diseases and corroborate the intricate link between cellular senescence, metabolism, and the circadian clock."

Journal • Genetic Disorders • Obesity • ARNTL • CDKN1A • CDKN2A

Effect of anti-obesity agent HSG4112 on overweight and obese patients following 12 weeks of oral treatment: a study protocol for a randomised, double-blind, placebo-controlled, parallel-group, phase 2a clinical trial. (PubMed, Front Pharmacol) - P2a | "This trial will evaluate the efficacy and safety of HSG4112 in overweight and obese adults. Upon proving the safety and effectiveness of the newly developed mechanism, it might significantly improve the perception of the product among medical personnel and obese patients. Furthermore, it may aid in managing chronic conditions that require long-term treatment. Trial registration: ClinicalTrials.gov, identifier [NCT05197556]."

Journal • P2a data • Genetic Disorders • Obesity

Vutiglabridin exerts anti-ageing effects in aged mice through alleviating age-related metabolic dysfunctions. (PubMed, Exp Gerontol) - "Vutiglabridin slows metabolic ageing mechanisms such as decreased insulin sensitivity, increased inflammation, and altered NAD metabolism in adipose tissue in mice experiments, while also retaining muscle homeostasis, which is deteriorated with age. It also improves the lipid profile in the blood and restores mitochondrial function in the liver to reduce ROS generation."

Journal • Preclinical • Inflammation • Metabolic Disorders • CDKN1A • CDKN2A

Vutiglabridin Modulates Paraoxonase 1 and Ameliorates Diet-Induced Obesity in Hyperlipidemic Mice. (PubMed, Biomolecules) - "We further investigated the effects of vutiglabridin in obese and hyperlipidemic LDLR mice and found that it significantly increases plasma PON1 levels, while decreasing body weight, total fat mass, and plasma cholesterol levels. Overall, our results demonstrate that PON1 is a direct, interacting target of vutiglabridin, and that the modulation of PON1 by vutiglabridin may provide benefits for the treatment of hyperlipidemia and obesity."

Journal • Preclinical • Dyslipidemia • Genetic Disorders • Metabolic Disorders • Obesity • PON1